1.Keefe R: Should cognitive impairment be included in the diagnostic criteria for schizophrenia? World Psychiatry. 2008; 7:22–28.
2.Green MF, Kern RS, Braff DL, Mintz J: Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”? Schizophr Bull. 2000; 26:119–136.
3.Goff DC, Hill M, Barch D: The treatment of cognitive impairment in schizophrenia. Pharmacol Biochem Behav. 2011; 99:245–253.
4.Kitchen H, Rofail D, Heron L, Sacco P: Cognitive impairment associated with schizophrenia: a review of the humanistic burden. Adv Ther. 2012; 29:148–162.
5.C Bowie PH: Cognitive deficits and functional outcome in schizophrenia. Neuropsychiatr Dis Treat. 2006; 2:531–536.
6.Webber MA, Marder SR: Better pharmacotherapy for schizophrenia: what does the future hold? Curr Psychiatry Rep. 2008; 10:352–358.
7.G Thornicroft MS: New trends in assessing the outcomes of mental health interventions. World Psychiatry. 2014; 13:118–124.
8.FDA: U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research, Guidance for industry and FDA staff: Qualification Process for Drug Development Tools. 2014.
9.Keefe RS, Poe M, Walker TM, Kang JW, Harvey PD: The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity. Am J Psychiatry. 2006; 163:426–432.
10.Velligan DI, Fredrick M, Mintz J, Li X, Rubin M, Dube S, Deshpande SN, Trivedi JK, Gautam S, Avasthi A, et al: The reliability and validity of the MATRICS functional assessment battery. Schizophr Bull. 2014; 40:1047–1052.
11.Fray PJ, Robbins TW: CANTAB battery: proposed utility in neurotoxicology. Neurotoxicol Teratol. 1996; 18:499–504.
12.Maruff P, Thomas E, Cysique L, Brew B, Collie A, Snyder P, Pietrzak RH: Validity of the CogState Brief Battery: Relationship to Standardized Tests and Sensitivity to Cognitive Impairment in Mild Traumatic Brain Injury, Schizophrenia, and AIDS Dementia Complex. Arch Clin Neuropsychol. 2009; 24:165–178.
13.Stip E, Caron J, Renaud S, Pampoulova T, Lecomte Y: Exploring cognitive complaints in schizophrenia: the subjective scale to investigate cognition in schizophrenia. Compr Psychiatry. 2003; 44:331–340.
14.Johnson I, Kebir O, Ben Azouz O, Dellagi L, Rabah Y, Tabbane K: The self-assessment scale of cognitive complaints in schizophrenia: a validation study in Tunisian population. BMC Psychiatry. 2009; 9:66.
15.Welch LC, Trudeau JJ, Silverstein SM, Sand M, Henderson DC, Rosen RC: Initial development of a patient-reported outcome measure of experience with cognitive impairment associated with schizophrenia. Patient Relat Outcome Meas. 2017; 8:71–81.
16.FDA: U.S. Department of Health Human Services Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health: Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. 2009.
17.American Educational Research Association, American Psychological Association, National Council on Measurement in Education: Standards for Educational and Psychological Testing. Washington, D.C.: American Educational Research Association; 2014.
18.Brown D, Nakagome K, Cordes J, Brenner R, Gründer G, Keefe RSE, Riesenberg R, Walling DP, Daniels K, Wang L, et al: Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial. Schizophr Bull. 2018; 45:350–359.
19.World Medical Association: World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013; 310:2191–2194.
20.Guidelines for good clinical practice E6 (revision 2) http://ichgcp.net/]
21.Nunnally JC BI: Psychometric Theory. 3rd Ed. edn: McGraw-Hill Inc, New York; 1994.
22.Cronbach L: Coefficient alpha and the internal structure of tests. Psychometrika 1951; 16:297–334.
23.Cohen J: Statistical Power Analysis for the Behavioral Sciences. 2nd edn. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
24.Wilson BA: Cognitive rehabilitation: how it is and how it might be. J Int Neuropsychol Soc. 1997; 3:487–496.
25.Silverstein SM, Hatashita-Wong M, Solak BA, Uhlhaas P, Landa Y, Wilkniss SM, Goicochea C, Carpiniello K, Schenkel LS, Savitz A, Smith TE: Effectiveness of a two-phase cognitive rehabilitation intervention for severely impaired schizophrenia patients. Psychol Med. 2005; 35:829–837.
26.Silverstein SM: Measuring specific, rather than generalized, cognitive deficits and maximizing between-group effect size in studies of cognition and cognitive change. Schizophr Bull. 2008; 34:645–655.
27.Silverstein SM, Roche MW, Khan Z, Carson SJ, Malinovsky I, Newbill WA, Menditto AA, Wilkniss SM: Enhancing and Promoting Recovery In Attentionally Impaired People Diagnosed With Schizophrenia: Results From A Randomized Controlled Trial Of Attention Shaping In A Partial Hospital Program. Am J Psychiatr Rehabil. 2014; 17:272–305.